Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Dipyridyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.93 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | CCR1 | P32246 | 3/20 | 0.93 |
| ▸ | CCR5 | P51681 | 3/20 | 0.93 |
| ▸ | CCR8 | P51685 | 3/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.93 |
| ▸ | POLB | P06746 | 1/20 | 0.93 |
| ▸ | METAP1 | P53582 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.93 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.93 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.93 |
| ▸ | NPC1 | O15118 | 6/20 | 0.74 |
| ▸ | TP53 | P04637 | 4/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipyridyl SCHEMBL3200307 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL27623647 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL27038595 | 1.00 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL7904091 | 0.97 | KDM4E (0.88) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL286888 | 0.97 | KDM4E (0.88) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29907716 | 0.97 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL5922 | 0.97 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL29351528 | 0.97 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL3711450 | 0.97 | KDM4E (1.00) | KDM4ELMNACCR1CCR5CCR8 | |
| Dipyridyl SCHEMBL9821490 | 0.93 | KDM4E (0.93) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707785-A | Bipyridine-based multifunctional ionic liquid and preparation method and application thereof | 湖南师范大学 | 2025-03-28 | — | — | CN | claimed |
| US-20250083137-A1 | SUPPORTED HYDROFORMYLATION CATALYST AND PREPARATION METHOD THEREOF, AND METHOD FOR SYNTHESIZING 4-ACETYLOXY-2-METHYL-2-BUTENAL | SHAOXING UNIVERSITY (CN) | 2025-03-13 | — | — | US | claimed |
| CN-119707785-A | Bipyridine-based multifunctional ionic liquid and preparation method and application thereof | 湖南师范大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20250083137-A1 | SUPPORTED HYDROFORMYLATION CATALYST AND PREPARATION METHOD THEREOF, AND METHOD FOR SYNTHESIZING 4-ACETYLOXY-2-METHYL-2-BUTENAL | SHAOXING UNIVERSITY (CN) | 2025-03-13 | — | — | US | disclosed |
| CN-118938553-A | Dual-network gel electrolyte for large-area electrochromic device and preparation method thereof | 宁波祢若电子科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-116903621-A | Preparation method of diquat salt | 安徽红太阳生物化学有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-1909912-B1 | Use of collismycin A as oxidative stress inhibitor | NOSCIRA SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| EP-2444121-A1 | Use of collismycin and derivatives thereof as oxidative stress inhibitors | Noscira, S.A. (ES) | 2012-04-25 | — | — | EP | disclosed |
| US-8067441-B2 | Use of collismycin and derivatives thereof as oxidative stress inhibitors | NEUROPHARMA, S.A. (ES) | 2011-11-29 | — | — | US | disclosed |
| US-20100048635-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | NEUROPHARMA, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | NEUROPHARMA, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| EP-1909912-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | Neuropharma S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007017146-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | NEUROPHARMA, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| EP-1749552-A1 | Use of collismycin and derivatives thereof as oxidative stress inhibitors | Neuropharma S.A. (ES) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250083137-A1 | SUPPORTED HYDROFORMYLATION CATALYST AND PREPARATION METHOD THEREOF, AND METHOD FOR SYNTHESIZING 4-ACETYLOXY-2-METHYL-2-BUTENAL | NQO1, PNN, HPGD | KDM4E 2645/4885LMNA 1604/4885CCR1 2158/4885 |
| US-20100048635-A2 | USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS | PARK7, HSPA9, NLN | KDM4E 4795/4885LMNA 1953/4885CCR1 4331/4885 |
| US-20080275088-A1 | Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors | PARK7, HSPA9, NLN | KDM4E 4795/4885LMNA 1953/4885CCR1 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.